{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:56Z","timestamp":1794047516055,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.288320","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:19:44Z","timestamp":1760599184000},"page":"1432-1435","source":"Crossref","is-referenced-by-count":1,"title":["Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers"],"prefix":"10.3324","volume":"111","author":[{"given":"Peter","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Hoegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajma","family":"Shahbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.G.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"88178","doi-asserted-by":"crossref","unstructured":"Palumbo A, Cavallo F, Gay F. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371(10):895-905.","DOI":"10.1056\/NEJMoa1402888"},{"key":"88179","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Marit G. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-1791.","DOI":"10.1056\/NEJMoa1114138"},{"key":"88180","doi-asserted-by":"crossref","unstructured":"Jackson GH, Davies FE, Pawlyn C. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20(1):57-73.","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"88181","doi-asserted-by":"crossref","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia. 2018; 32(2):383-390.","DOI":"10.1038\/leu.2017.211"},{"key":"88182","doi-asserted-by":"crossref","unstructured":"Goel U, Kumar S. An update on the safety of ixazomib for the treatment of multiple myeloma. Expert Opin Drug Saf. 2022; 21(9):1143-1160.","DOI":"10.1080\/14740338.2022.2130892"},{"key":"88183","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Gay F, Schjesvold F. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebocontrolled phase 3 trial. Lancet. 2019; 393(10168):253-264.","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"88184","doi-asserted-by":"crossref","unstructured":"L\u00f6ffler H, Braun M, Reinhardt H. Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature. Ann Hematol. 2025; 104(7):3713-3722.","DOI":"10.1007\/s00277-025-06441-8"},{"key":"88185","doi-asserted-by":"crossref","unstructured":"Li J, Bao L, Xia Z. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020; 99(11):2589-2598.","DOI":"10.1007\/s00277-020-04234-9"},{"key":"88186","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024; 99(9):1802-1824.","DOI":"10.1002\/ajh.27422"},{"key":"88187","doi-asserted-by":"crossref","unstructured":"Shen M, Zhang J, Tang R. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: a real-world study. Cancer Med. 2022; 11(11):2173-2183.","DOI":"10.1002\/cam4.4313"},{"key":"88188","doi-asserted-by":"crossref","unstructured":"Xu Y, Zhang X, Wang L. Real-world data of maintenance therapy for newly diagnosed multiple myeloma: ixazomib versus lenalidomide. Blood. 2024; 144(Suppl 1):3792-3793.","DOI":"10.1182\/blood-2024-205549"},{"key":"88189","doi-asserted-by":"crossref","unstructured":"Goldschmidt H, Dimopoulos MA, Rajkumar SV. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. 2020; 34(11):3019-3027.","DOI":"10.1038\/s41375-020-0819-8"},{"key":"88190","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 390(4):301-313.","DOI":"10.1056\/NEJMoa2312054"},{"key":"88191","doi-asserted-by":"crossref","unstructured":"Zamagni E, Boccadoro M, Spencer A. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2022; 140(Suppl 1):7289-7291.","DOI":"10.1182\/blood-2022-159756"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12945\/78936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12945\/79880","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12945\/78936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:02Z","timestamp":1794046202000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288320","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}